公开(公告)号：US20150291617A1

公开(公告)日：2015-10-15

申请号：US14379134

申请日：2013-02-22

申请人： LUPIN LIMITED

发明人： Neelima Sinha ,  Navnath Popat Karche ,  Anil Kashiram Hajare ,  Shridhar Keshav Adurkar ,  Bikramjit Singh Lairikyengbam ,  Firoj Aftab Raje ,  Ajay Ramchandra Tilekar ,  Baban Rupaji Thube ,  Venkata P. Palle ,  Rajender Kumar Kamboj

IPC分类号： C07D498/08 ,  C07D221/22 ,  A61K31/439 ,  C07D417/06 ,  A61K45/06 ,  C07D277/56 ,  A61K31/454 ,  C07D417/04 ,  A61K31/427 ,  A61K31/5386 ,  A61K31/5377

CPC分类号： C07D498/08 ,  A61K31/427 ,  A61K31/439 ,  A61K31/454 ,  A61K31/5377 ,  A61K31/5386 ,  A61K45/06 ,  C07D221/22 ,  C07D277/56 ,  C07D417/04 ,  C07D417/06 ,  C07D417/14

摘要： Disclosed is a compound of formula (I) wherein Y, Ring D, m and R1-R4 are as described herein, as a modulator of nicotinic acetylcholine receptors particularly the α7 subtype, in a subject in need thereof, as well as pharmaceutically acceptable salts, polymorphs, solvates, and isomers thereofs, for use either alone or in combinations with suitable other medicaments, and pharmaceutical compositions containing such compounds. Also disclosed are a process of preparation of the compounds and the intended uses thereof in therapy, particularly in the prophylaxis and therapy of disorders such as Alzheimer's disease, mild cognitive impairment, senile dementia, and the like.

摘要翻译： 公开了其中Y，环D，m和R 1 -R 4如本文所述的式（I）化合物，作为需要其的受试者中烟碱乙酰胆碱受体，特别是α7亚型的调节剂，以及药学上可接受的盐 ，多晶型物，溶剂合物和异构体，单独使用或与合适的其它药物组合使用，以及含有这些化合物的药物组合物。 还公开了化合物的制备方法及其在治疗中的用途，特别是在诸如阿尔茨海默氏病，轻度认知障碍，老年痴呆等疾病的预防和治疗中。

公开(公告)号：US20150010505A1

公开(公告)日：2015-01-08

申请号：US14375534

申请日：2013-02-08

申请人： Lupin Limited

发明人： Vidya Ramdas ,  Advait Arun Joshi ,  Moloy Manoj Banerjee ,  Amit Kumar Das ,  Deepak Sahebrao Walke ,  Venkata P. Palle ,  Rajender Kumar Kamboj

IPC分类号： C07D405/14 ,  A61K45/06 ,  A61K31/4178

CPC分类号： C07D495/04 ,  A61K31/4178 ,  A61K31/428 ,  A61K45/06 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14 ,  Y02A50/463

摘要： Disclosed are compounds of formula (I) for use as antiviral agents, particularly as anti-hepatitis virus C agents, wherein R-R 6 and q are as described herein. Also disclosed are pharmaceutical compositions and methods of treating or preventing viral infection in a host by the use of these compounds, either alone or in combination with other pharmaceutically active agents. Further disclosed are methods of preparing such compounds. (I).

摘要翻译： 公开了用作抗病毒剂的式（I）化合物，特别是作为抗肝炎病毒C试剂，其中R-R 6和q如本文所述。 还公开了通过使用这些化合物单独或与其它药物活性剂组合来治疗或预防宿主中病毒感染的药物组合物和方法。 进一步公开的是制备这些化合物的方法。 （一世）。

公开(公告)号：US11952380B2

公开(公告)日：2024-04-09

申请号：US17738370

申请日：2022-05-06

申请人： LUPIN LIMITED

发明人： Prathap Sreedharan Nair ,  Ganesh Bhausaheb Gudade ,  Sachin Sethi ,  Dipak Raychand Lagad ,  Chetan Sanjay Pawar ,  Mahadeo Bhaskar Tryambake ,  Chaitanya Prabhakar Kulkarni ,  Anil Kashiram Hajare ,  Balasaheb Arjun Gore ,  Sanjeev Anant Kulkarni ,  Milind Dattatraya Sindkhedkar ,  Venkata P. Palle ,  Rajender Kumar Kamboj

IPC分类号： A61K31/519 ,  A61K31/53 ,  A61P35/00 ,  C07D471/04 ,  C07D487/04 ,  C07D519/00

CPC分类号： C07D487/04 ,  A61P35/00 ,  C07D471/04 ,  C07D519/00

摘要： The invention relates to substituted bicyclic heterocyclic compounds of formula (I), pharmaceutically acceptable salts thereof and pharmaceutical compositions for treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme. The invention also relates to methods of treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme.

公开(公告)号：US11459330B2

公开(公告)日：2022-10-04

申请号：US16772959

申请日：2018-12-13

申请人： LUPIN LIMITED

发明人： Prathap Sreedharan Nair ,  Ganesh Bhausaheb Gudade ,  Sachin Sethi ,  Dipak Raychand Lagad ,  Chetan Sanjay Pawar ,  Mahadeo Bhaskar Tryambake ,  Chaitanya Prabhakar Kulkarni ,  Anil Kashiram Hajare ,  Balasaheb Arjun Gore ,  Sanjeev Anant Kulkarni ,  Milind Dattatraya Sindkhedkar ,  Venkata P. Palle ,  Rajender Kumar Kamboj

IPC分类号： C07D471/04 ,  C07D487/04 ,  A61K31/519 ,  A61K31/53 ,  A61P35/00 ,  C07D519/00

摘要： The invention relates to substituted bicyclic heterocyclic compounds of formula (I), pharmaceutically acceptable salts thereof and pharmaceutical compositions for treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme. The invention also relates to methods of treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme.

公开(公告)号：US20210163486A1

公开(公告)日：2021-06-03

申请号：US16772959

申请日：2018-12-13

申请人： LUPIN LIMITED

发明人： Prathap Sreedharan Nair ,  Ganesh Bhausaheb Gudade ,  Sachin Sethi ,  Dipak Raychand Lagad ,  Chetan Sanjay Pawar ,  Mahadeo Bhaskar Tryambake ,  Chaitanya Prabhakar Kulkarni ,  Anil Kashiram Hajare ,  Balasaheb Arjun Gore ,  Sanjeev Anant Kulkarni ,  Milind Dattatraya Sindkhedkar ,  Venkata P. Palle ,  Rajender Kumar Kamboj

IPC分类号： C07D487/04 ,  A61P35/00 ,  C07D519/00 ,  C07D471/04

摘要： The invention relates to substituted bicyclic heterocyclic compounds of formula (I), pharmaceutically acceptable salts thereof and pharmaceutical compositions for treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme. The invention also relates to methods of treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme.

公开(公告)号：US20210052556A1

公开(公告)日：2021-02-25

申请号：US16831301

申请日：2020-03-26

申请人： Lupin Limited

发明人： Gagan Kukreja ,  Nageswara Rao Irlapati ,  Arun Rangnath Jagdale ,  Gokul Keruji Deshmukh ,  Vinod Popatrao Vyavahare ,  Kiran Chandrashekhar Kulkarni ,  Neelima Sinha ,  Venkata P. Palle ,  Rajender Kumar Kamboj

IPC分类号： A61K31/429 ,  C07D513/04 ,  A61P37/00 ,  A61P35/02 ,  A61P11/00

摘要： Disclosed are compounds of the general formula (I), wherein R1-R3 are as defined herein, for use as MALT1 inhibitors in the treatment of autoimmune and inflammatory diseases or disorders. Methods of synthesizing the compounds are also disclosed. Also disclosed are pharmaceutical compositions containing a compound of the invention and a method of treating a patient for an autoimmune or an inflammatory disease or disorder, for example, a cancer, by administering a compound of the invention.

公开(公告)号：US09617210B2

公开(公告)日：2017-04-11

申请号：US14655476

申请日：2014-03-12

申请人： Lupin Limited

发明人： Neelima Sinha ,  Navnath Popat Karche ,  Shridhar Keshav Adurkar ,  Venkata P. Palle ,  Rajender Kumar Kamboj

IPC分类号： C07D207/323 ,  A61K45/06 ,  A61K31/401 ,  C07D401/04 ,  C07D403/06 ,  C07D207/34

CPC分类号： C07D207/323 ,  A61K31/401 ,  A61K45/06 ,  C07D207/34 ,  C07D401/04 ,  C07D403/06

摘要： Disclosed are compounds of the Formula (I), wherein R1, R2, R3, R4, R5, R6, R7 and m are as described herein, as modulators of the nicotinic acetylcholine receptors, particularly the α7 subtype, their tautomeric forms, stereoisomers, and their pharmaceutically acceptable salts, pharmaceutical compositions thereof, and combinations thereof with suitable other medicaments. Also disclosed are a process of preparation of the compounds and the intended uses thereof in therapy, particularly in the prophylaxis and/or treatment of disorders such as Alzheimer's disease, mild cognitive impairment, and senile dementia.

公开(公告)号：US09598391B2

公开(公告)日：2017-03-21

申请号：US14842141

申请日：2015-09-01

申请人： LUPIN LIMITED

发明人： Manojkumar Ramprasad Shukla ,  Ankush Gangaram Sarde ,  Rajeshkumar Maganlal Loriya ,  Vipul Dilip Pachpute ,  Navnath Bajirao Walke ,  Talha Hussain Khan ,  Sanjeev Anant Kulkarni ,  Venkata P. Palle ,  Rajender Kumar Kamboj

IPC分类号： C07D311/58 ,  C07D405/10 ,  A61K31/4025 ,  A61K31/353

CPC分类号： A61K31/352 ,  A61K31/353 ,  A61K31/4025 ,  C07D311/02 ,  C07D311/58 ,  C07D405/10

摘要： The present invention provides calcium sensing receptor modulators (CaSR). In particular, the compounds described herein are useful for treating, managing, and/or lessening the severity of diseases, disorders, syndromes and/or conditions associated with the modulation of calcium sensing receptors (CaSR). The invention also provides herein the pharmaceutical compositions thereof, and methods for treating, managing, and/or lessening the severity of diseases, disorders, syndromes and/or conditions associated with the modulation of CaSR. The invention also relates to process for the preparation of the compounds of the invention.

公开(公告)号：US09393247B2

公开(公告)日：2016-07-19

申请号：US14705144

申请日：2015-05-06

申请人： Lupin Limited

发明人： Neelima Sinha ,  Gourhari Jana ,  Sachchidanand Sachchidanand ,  Sanjay Pralhad Kurhade ,  Navnath Popat Karche ,  Anil Kashiram Hajare ,  Ajay Ramchandra Tilekar ,  Venkata P. Palle ,  Rajender Kumar Kamboj

IPC分类号： A61K31/40 ,  A61K31/381 ,  A61K31/341 ,  A61K31/5377 ,  A61K31/4535 ,  A61K45/06

CPC分类号： A61K31/5377 ,  A61K31/341 ,  A61K31/381 ,  A61K31/40 ,  A61K31/404 ,  A61K31/4436 ,  A61K31/4535 ,  A61K31/496 ,  A61K45/06 ,  C07D207/32 ,  C07D207/333 ,  C07D207/337 ,  C07D307/68 ,  C07D333/22 ,  C07D333/26 ,  C07D333/36 ,  C07D333/38 ,  C07D409/04 ,  A61K2300/00

摘要： Disclosed is a compound of formula I: wherein Z, m and R1-R6 are as described herein, as a modulator of nicotinic acetylcholine receptors particularly the α7 subtype, in a subject in need thereof, as well as analogues, prodrugs, isotopically substituted analogs, metabolites, pharmaceutically acceptable salts, polymorphs, solvates, isomers, clathrates, and co-crystal thereof, for use either alone or in combinations with suitable other medicaments, and pharmaceutical compositions containing such compounds and analogues. Also disclosed are a process of preparation of the compounds and the intended uses thereof in therapy, particularly in the prophylaxis and therapy of disorders such as Alzheimer's disease, mild cognitive impairment, senile dementia, and the like.

摘要翻译： 公开了式I化合物：其中Z，m和R 1 -R 6如本文所述，作为有需要的受试者中烟碱乙酰胆碱受体，特别是α7亚型的调节剂，以及类似物，前药，同位素取代的类似物 ，代谢产物，药学上可接受的盐，多晶型物，溶剂化物，异构体，包合物和共结晶，单独使用或与合适的其它药物组合使用，以及含有这些化合物和类似物的药物组合物。 还公开了化合物的制备方法及其在治疗中的用途，特别是在诸如阿尔茨海默氏病，轻度认知障碍，老年痴呆等疾病的预防和治疗中。

公开(公告)号：US20150361041A1

公开(公告)日：2015-12-17

申请号：US14655878

申请日：2014-01-13

申请人： LUPIN LIMITED

发明人： Neelima Sinha ,  Navnath Popat Karche ,  Anil Kashiram Hajare ,  Baban Rupaji Thube ,  Dnyaneshwar Changdeo Bhanage ,  Venkata P. Palle ,  Rajender Kumar Kamboj

IPC分类号： C07D207/333 ,  A61K45/06 ,  A61K31/403 ,  A61K31/40 ,  C07D403/06

CPC分类号： C07D207/333 ,  A61K31/40 ,  A61K31/403 ,  A61K45/06 ,  C07D207/33 ,  C07D207/416 ,  C07D403/06 ,  Y02A50/411

摘要： Disclosed is a compound of formula (I), wherein R1, R2, R3, R4, R5, R6, R7 and m are as described herein, as a modulator of nicotinic acetylcholine receptors particularly α7 subtype, its tautomeric forms, its stereoisomers, its pharmaceutically acceptable salts, its pharmaceutical composition, and its combinations with suitable medicaments. Also disclosed are a process of preparation of the compounds and the intended uses thereof in therapy, particularly in the prophylaxis and therapy of disorders such as Alzheimer's disease, mild cognitive impairment, senile dementia, and the like.

摘要翻译： 公开了式（I）化合物，其中R 1，R 2，R 3，R 4，R 5，R 6，R 7和m如本文所述，作为烟碱型乙酰胆碱受体的调节剂，特别是α7亚型，其互变异构形式，其立体异构体，其 药学上可接受的盐，其药物组合物及其与合适药物的组合。 还公开了化合物的制备方法及其在治疗中的用途，特别是在诸如阿尔茨海默氏病，轻度认知障碍，老年痴呆等疾病的预防和治疗中。